Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

ER stress response is major driver of insulin resistance, say researchers

Biologists have long known that an enzyme called the PI 3-kinase is a crucial actor in the main molecular pathway for insulin signaling in cells. Researchers at Joslin Diabetes Center now have uncovered startling evidence that one of the proteins in this enzyme also drives a pathway with an opposite result-triggering a stress response that leads to insulin resistance.

29 Mar 2010

New approach may circumvent lost response in insulin due to obesity

Researchers at Children's Hospital Boston have identified a new strategy for treating type 2 diabetes, identifying a cellular pathway that fails when people become obese. By activating this pathway artificially, they were able to normalize blood glucose levels in severely obese and diabetic mice. Their findings will be published online by Nature Medicine on March 28.

29 Mar 2010

FDA Advisory Committee to review VIVUS' NDA for Qnexa

VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration is tentatively scheduled to review the Company's New Drug Application for Qnexa® for the treatment of obesity on July 15, 2010.

26 Mar 2010

New topical drug may help treat diabetic eye disease

Early-stage human clinical trials showed that a new topical drug was safe and had biological effects in a type of diabetic eye disease, and may offer researchers a new approach to prevent and treat diabetic macular edema.

26 Mar 2010

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).

26 Mar 2010

Santarus enrolls 510 patients in Phase III clinical program for budesonide MMX

Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.

26 Mar 2010

Independent DMC recommends continuance of enrollment in Eisai's Phase III ACCESS trial

Eisai Inc. announced today that the Phase III ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial of the investigational compound eritoran (E5564) will continue enrolling to the preset goal of 2,000 patients. As part of a planned interim analysis, an independent Data Monitoring Committee (DMC) has evaluated efficacy and safety data on the first 1,500 subjects to complete the 28-day follow-up in the Phase III ACCESS trial.

26 Mar 2010

EVMS researchers awarded $1,076,250 grant to develop functional cure for Type 1 diabetes

Researchers at the Eastern Virginia Medical School Strelitz Diabetes Center have been awarded a $1,076,250 grant by the Department of Defense Peer Reviewed Medical Research Program to develop new ways of reversing the underlying causes of Type 1 diabetes.

26 Mar 2010

DARA BioSciences announces the initiation of Phase I clinical study for DB959

DARA BioSciences, Inc. announced that it has initiated a Phase I clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes. The study will enroll approximately 75 volunteers and will be conducted at Quintiles' Overland Park facility.

26 Mar 2010

Findings suggest adipose inflammation is necessary for fat cell turnover

It has been a common opinion that inflammation in adipose tissue may cause insulin resistance, and thereby type 2 diabetes. However, recent research from the Swedish medical university Karolinska Institutet, published in the New England Journal of Medicine, question the theory that inflammation in the body fat is only pernicious.

25 Mar 2010

NIH grant for study on impact of gastric bypass surgery on Type II diabetes patients

Gastric bypass surgery, thought of by many as the last hope of morbidly obese people for losing weight, has many other benefits researchers are only beginning to understand.

25 Mar 2010

China, now the largest diabetic population in the world

With one in ten adults in China being diagnosed with diabetes the largest population of the world is also the largest diabetic population in the world. A report published by New England Journal of Medicine reported that 92 million people in China were diabetic. This means China has overtaken India which had a 50 million strong diabetic population to date.

25 Mar 2010

Bariatric surgery may delay onset of type 2 diabetes, says study

A team of researchers, led by a UC Davis veterinary endocrinologist, has shown for the first time that a surgical procedure in rats that is similar to bariatric surgery in humans can delay the onset of type 2 diabetes.

25 Mar 2010

New study shows leptin treatment may help reduce type 1 diabetes

Using leptin alone in place of standard insulin therapy shows promise in abating symptoms of type 1 diabetes, UT Southwestern Medical Center researchers report.

24 Mar 2010

FDA grants Orphan Drug Designation for anti-diabetic drug

The FDA has granted Orphan Drug Designation of Diamyd Medical´s lead drug candidate Diamyd®. Orphan drugs qualify for seven years of market exclusivity from the date of US marketing approval, tax credits for clinical research and a waiver for FDA user fees.

24 Mar 2010

Researchers create audio CDs to encourage physical activity among school students

The National Institutes of Health has awarded Albert Einstein College of Medicine of Yeshiva University $1.22 million to combat childhood obesity in the Bronx.

24 Mar 2010

Walgreens's fiscal 2010 second-quarter sales up 3.1% to $17.0 billion

Walgreens today announced earnings and sales for the second quarter of fiscal year 2010.

23 Mar 2010

School-based program raises awareness about preventing type 2 diabetes

It is well known that type 2 diabetes is largely a preventable chronic disease with proper nutrition, regular physical activity and the maintenance of a healthy body weight. Yet despite growing awareness, the Canadian Diabetes Association (CDA) reports that more than three million Canadians currently have diabetes, with an overwhelming 90% of cases reflecting type 2 diabetes. The CDA also suggests that a child born in the year 2000 has a frightening 1 in 3 chance of developing diabetes.

23 Mar 2010

Novo Nordisk Foundation donates $160M to University of Copenhagen for metabolic research

The Center will conduct research into Type 2 diabetes, among other diseases, and will acquire the capacities and resources to establish itself as one of the leading international research centers in the world. With 885 million Danish kroner (approx. 160 million US Dollars) from the Novo Nordisk Foundation, a team of 5 leading research scientists will be headhunted by the University to oversee "The Novo Nordisk Foundation Center for Basic Metabolic Research".

From Novo Nordisk 23 Mar 2010

T1D and IBD may respond to 2-way genetic switch: Study

Pediatric researchers analyzing DNA variations in type 1 diabetes and inflammatory bowel disease have found a complex interplay of genes. Some genes have opposing effects, raising the risk of one disease while protecting against the other. In other cases, a gene variant may act in the same direction, raising the risk for both diseases.

23 Mar 2010

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

ER stress response is major driver of insulin resistance, say researchers

New approach may circumvent lost response in insulin due to obesity

FDA Advisory Committee to review VIVUS' NDA for Qnexa

New topical drug may help treat diabetic eye disease

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Santarus enrolls 510 patients in Phase III clinical program for budesonide MMX

Independent DMC recommends continuance of enrollment in Eisai's Phase III ACCESS trial

EVMS researchers awarded $1,076,250 grant to develop functional cure for Type 1 diabetes

DARA BioSciences announces the initiation of Phase I clinical study for DB959

Findings suggest adipose inflammation is necessary for fat cell turnover

NIH grant for study on impact of gastric bypass surgery on Type II diabetes patients

China, now the largest diabetic population in the world

Bariatric surgery may delay onset of type 2 diabetes, says study

New study shows leptin treatment may help reduce type 1 diabetes

FDA grants Orphan Drug Designation for anti-diabetic drug

Researchers create audio CDs to encourage physical activity among school students

Walgreens's fiscal 2010 second-quarter sales up 3.1% to $17.0 billion

School-based program raises awareness about preventing type 2 diabetes

Novo Nordisk Foundation donates $160M to University of Copenhagen for metabolic research

T1D and IBD may respond to 2-way genetic switch: Study

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in